EAN 2025: A Fundamental Shift in Myasthenia Gravis Treatment on the Horizon

At the Nordic Evening during EAN 2025, Professor Nils Erik Gilhus offered a compelling overview of current and emerging perspectives on myasthenia gravis. In his MEDtalk, he focused on the development and implementation of novel therapies—particularly the accessibility of these treatments within the Nordic region.
Professor Gilhus expressed strong confidence that we are approaching a significant transformation in the treatment landscape for myasthenia gravis. He anticipates a future where advanced pharmacological options will be effectively integrated with non-pharmacological approaches, leading to substantially improved outcomes for patients.